1. Home
  2. SKYE vs FCCO Comparison

SKYE vs FCCO Comparison

Compare SKYE & FCCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • FCCO
  • Stock Information
  • Founded
  • SKYE 2012
  • FCCO 1994
  • Country
  • SKYE United States
  • FCCO United States
  • Employees
  • SKYE N/A
  • FCCO N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • FCCO Major Banks
  • Sector
  • SKYE Health Care
  • FCCO Finance
  • Exchange
  • SKYE Nasdaq
  • FCCO Nasdaq
  • Market Cap
  • SKYE 73.4M
  • FCCO 182.4M
  • IPO Year
  • SKYE N/A
  • FCCO 1998
  • Fundamental
  • Price
  • SKYE $4.17
  • FCCO $25.42
  • Analyst Decision
  • SKYE Buy
  • FCCO Strong Buy
  • Analyst Count
  • SKYE 6
  • FCCO 2
  • Target Price
  • SKYE $16.60
  • FCCO $30.00
  • AVG Volume (30 Days)
  • SKYE 2.0M
  • FCCO 77.0K
  • Earning Date
  • SKYE 08-08-2025
  • FCCO 07-23-2025
  • Dividend Yield
  • SKYE N/A
  • FCCO 2.36%
  • EPS Growth
  • SKYE N/A
  • FCCO 37.48
  • EPS
  • SKYE N/A
  • FCCO 1.98
  • Revenue
  • SKYE N/A
  • FCCO $67,933,000.00
  • Revenue This Year
  • SKYE N/A
  • FCCO $18.61
  • Revenue Next Year
  • SKYE N/A
  • FCCO $11.88
  • P/E Ratio
  • SKYE N/A
  • FCCO $12.84
  • Revenue Growth
  • SKYE N/A
  • FCCO 16.46
  • 52 Week Low
  • SKYE $1.14
  • FCCO $16.06
  • 52 Week High
  • SKYE $8.26
  • FCCO $27.96
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 71.01
  • FCCO 71.18
  • Support Level
  • SKYE $3.41
  • FCCO $21.80
  • Resistance Level
  • SKYE $5.75
  • FCCO $23.84
  • Average True Range (ATR)
  • SKYE 0.57
  • FCCO 0.63
  • MACD
  • SKYE 0.16
  • FCCO 0.27
  • Stochastic Oscillator
  • SKYE 57.41
  • FCCO 99.45

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About FCCO First Community Corporation

First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are; Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.

Share on Social Networks: